Background/aims: Octreotide acutely decreases splanchnic blood flow and postprandial portal pressure in patients with portal hypertension. Inhibition of glucagon release parallels the hemodynamic changes. We studied the hormonal and renal effects of long-term treatment with octreotide (100 microg s.c., t.i.d., immediately before meals, for 2 weeks) in 12 patients with cirrhosis and portal hypertension.
Methods: Postprandial blood levels of glucagon, insulin and glucose, and renal function tests were monitored in a study where patients acted as their own controls. Eleven patients completed the study, octreotide being discontinued in one patient who developed jaundice after 6 days of therapy.
Results: Long-term treatment did not cause any change in fasting hormonal levels measured 12 h after the last injection of octreotide. However, pre-prandial injection of octreotide induced a marked fall in blood glucagon (163+/-49 pg/ml, after 20 min, vs. 254+/-71 pg/ml, basal; p<0.01), thus preventing the postprandial response occurring without treatment (322+/-102 pg/ml, 30 min-peak, vs. 249+/-77 pg/ml, basal; p<0.03). Inhibition of postprandial glucagon was maintained after 2 weeks of therapy (159+/-33 pg/ml, after 20 min, vs. 237+/-54 pg/ml, basal; p<0.01). Octreotide abolished the insulin postprandial response with no major change in glycemic control. Treatment had no long-term effect on renal plasma flow (effective renal plasma flow: 596+/-79 ml/min, baseline, vs. 609+/-71 ml/min, at 2 weeks; p>0.5), glomerular filtration rate (glomerular filtration rate: 99+/-11 vs. 99+/-12 ml/min; p>0.5), blood urea and creatinine, whereas it induced a mild decrease in plasma electrolyte levels (p<0.02).
Conclusions: Long-term octreotide treatment persistently suppresses the postprandial glucagon response of patients with portal hypertension without causing deterioration in their renal function.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0168-8278(97)80247-4 | DOI Listing |
J Mater Chem B
January 2025
Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Department of Ophthalmology, Reina Sofia University Hospital and University of Cordoba, 14004 Cordoba, Spain.
Gold nanoparticles (AuNPs) play a key role in the field of nanomedicine due to their fascinating plasmonic properties as well as their great biocompatibility. An intriguing application is the use of plasmonic photothermal therapy (PPTT) mediated by anisotropic AuNPs irradiated with a near-infrared (NIR) laser for treating ocular diseases in ophthalmology. For this purpose, bipyramidal-shaped AuNPs (BipyAu), which were surface-functionalized with three different organic ligands (citrate, polystyrene sulphonate (PSS), and cetyltrimethylammonium bromide (CTAB)), were synthesized.
View Article and Find Full Text PDFHypertension
January 2025
Accelerator for Clinical Transformation, Brigham and Women's Hospital, Boston, MA. (S.H., A.J.B., D.Z., S.K., K.W., D.G., C.P.C., B.M.S.).
Background: Hypertension is a major cardiovascular risk factor, yet traditional care often results in suboptimal blood pressure (BP) control at the population level. We implemented a remote hypertension management program that monitored home BP and titrated medications per algorithm. This study assessed the program's long-term effects by examining participants' office BP up to 42 months post-enrollment.
View Article and Find Full Text PDFCureus
December 2024
Emergency Medicine, King Abdulaziz University Hospital, Jeddah, SAU.
Background: Elevated blood pressure (BP) prompts immediate emergency department (ED) visits instead of outpatient care, thus constituting a high-weight concern for the ED. This study investigated the short- and long-term outcomes of high BP patients in the ED.
Methods: A retrospective cohort study was conducted at King Abdulaziz University Hospital (KAUH), reviewing ED visits from January to December 2022.
Cureus
December 2024
Medicine, Universidad Santiago de Cali, Cali, COL.
Ventricular tachycardia (VT) is a life-threatening arrhythmia often leading to sudden cardiac death, particularly in critically ill patients. Refractory VT, characterized by recurrent episodes requiring intervention, poses unique challenges for management, necessitating advanced diagnostic and therapeutic strategies. This systematic review evaluates the impact of imaging and pharmacological treatments in managing refractory VT in critically ill patients.
View Article and Find Full Text PDFFront Oncol
January 2025
Comprehensive Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Introduction: This retrospective study aims to evaluate the long-term efficacy and urinary toxicity of LDR-brachytherapy for localized prostate cancer.
Materials And Methods: 235 primary prostate cancer patients treated with LDR-brachytherapy and subsequently followed up in our center were included in this study. Biochemical relapse free survival (bRFS), overall survival (OS), and cancer-specific survival (CSS) were evaluated.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!